Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Raven-Symoné recalls being pushed to alter her body in order to get a television show at the tender age of 15.

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Meta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half ...

The Institute of Cancer Research believes that animal research is essential to understand how cancers develop within a whole organism, and how to treat it.

The findings from the study demonstrated a substantial decrease in reoperation rates when the Histolog scanner was utilised.

After a median follow-up of 6.1 years, patients treated with Lynparza continued to show significant improvements in survival ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a ...

Biovica signed an agreement with US Biotech company in clinical phase Biovica received a significant order for TKa testing services Biovica published the outcome of exercise of warrants from series ...

The median time from breast cancer diagnosis to surgery was 0.8 years for risk-reducing mastectomies and three years for risk ...